These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33511892)

  • 1. Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
    Aksan A; Dignass A; Stein J
    Expert Rev Hematol; 2022 Apr; 15(4):383-384. PubMed ID: 33511892
    [No Abstract]   [Full Text] [Related]  

  • 2. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
    Pollock RF; Biggar P
    Expert Rev Hematol; 2020 Feb; 13(2):187-195. PubMed ID: 31928094
    [No Abstract]   [Full Text] [Related]  

  • 3. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
    Pollock RF; Kalra PA; Kalra PR; Ahmed FZ
    Adv Ther; 2022 Oct; 39(10):4678-4691. PubMed ID: 35947351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
    Hu S; Liu L; Pollock RF; Pöhlmann J; Wu D; Zhang Y
    J Med Econ; 2022; 25(1):561-570. PubMed ID: 35403540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for treating iron deficiency anaemia in inflammatory bowel disease.
    Gordon M; Sinopoulou V; Iheozor-Ejiofor Z; Iqbal T; Allen P; Hoque S; Engineer J; Akobeng AK
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013529. PubMed ID: 33471939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
    Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
    Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia.
    Derman R; Roman E; Smith-Nguyen GN; Achebe MM; Thomsen LL; Auerbach M
    Am J Hematol; 2018 Jun; 93(6):E148-E150. PubMed ID: 29569727
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial.
    Jose A; Mahey R; Sharma JB; Bhatla N; Saxena R; Kalaivani M; Kriplani A
    BMC Pregnancy Childbirth; 2019 Feb; 19(1):54. PubMed ID: 30717690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
    Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
    J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials.
    Naqash A; Ara R; Bader GN
    BMC Womens Health; 2018 Jan; 18(1):6. PubMed ID: 29304848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
    Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
    Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review.
    Qassim A; Mol BW; Grivell RM; Grzeskowiak LE
    Aust N Z J Obstet Gynaecol; 2018 Feb; 58(1):22-39. PubMed ID: 28921558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.
    Kawabata H; Tamura T; Tamai S; Fujibayashi A; Sugimura M;
    Int J Hematol; 2022 Nov; 116(5):647-658. PubMed ID: 35790696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery.
    Auerbach M; Achebe MM; Thomsen LL; Derman RJ
    Obes Surg; 2022 Mar; 32(3):810-818. PubMed ID: 35000068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of parenteral iron in children with inflammatory bowel disease.
    Papadopoulos M; Patel D; Korologou-Linden R; Goto E; Soondrum K; Fell JME; Epstein J
    Br J Clin Pharmacol; 2018 Apr; 84(4):694-699. PubMed ID: 29266387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review.
    Bazeley JW; Wish JB
    Am J Kidney Dis; 2022 Jun; 79(6):868-876. PubMed ID: 34758368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data.
    Brock E; Braunhofer P; Troxler J; Schneider H
    Eur J Health Econ; 2014 Dec; 15(9):907-16. PubMed ID: 24081613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.